Ming‐Mo Hou - Concepedia

Author

Ming‐Mo Hou

Chang Gung Memorial Hospital

Also Known As

M. Hou, M.-M. Hou, M.M. Hou, ManTing Hou, Manting Hou, Mengqian Hou, Ming-Mo Hou, Mingfu Hou, Mingyong HOU, Ming‐Mo Hou

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Chang Gung Memorial Hospital Chang Gung University Linkou Chang Gung Memorial Hospital Kaohsiung Chang Gung Memorial Hospital Soochow University

About

Ming‐Mo Hou is an author at Chang Gung Memorial Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	582
2	Health Sciences	6	6	366
3	Nursing	3	3	86
4	Arts	1	1	18
5	Cell Biology	1	1	72

Ming‐Mo Hou

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis Thomas Yau, Chiun Hsu, Tae‐You Kim, Journal of Hepatology	2019	267
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B. Sangro, Stephen L. Chan, Robin Kate Kelley, Annals of Oncology	2024	254
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Journal of Clinical Oncology PharmacotherapyNivo MonotherapyPre-clinical PharmacologyOncologyObjective Response Rate	2019	225
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation Siqing Fu, Ming‐Mo Hou, Aung Naing, Annals of Oncology Mutant P53 DegradationMutant P53-mediated AngiogenesisAngiogenesisMedicineVascular Biology	2015	72
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial Zhenggang Ren, Michel Ducreux, Ghassan K. Abou‐Alfa, Liver Cancer	2022	71
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. Anthony B. El-Khoueiry, Thomas Yau, Yoon‐Koo Kang, Journal of Clinical Oncology PharmacotherapyMinimum Follow-upPre-clinical PharmacologyTranslational PharmacologyOncology	2021	51
Accurate Prognostic Awareness Facilitates, Whereas Better Quality of Life and More Anxiety Symptoms Hinder End-of-Life Care Discussions: A Longitudinal Survey Study in Terminally Ill Cancer Patients' Last Six Months of Life Siew Tzuh Tang, Chen Hsiu Chen, Fur‐Hsing Wen, Journal of Pain and Symptom Management Palliative CareQuality Of LifeNursingFamily MedicineEnd-of-life Care	2017	45
Impact of high self-perceived burden to others with preferences for end-of-life care and its determinants for terminally ill cancer patients: a prospective cohort study Siew Tzuh Tang, Chia‐Hsun Hsieh, Ming-Chu Chiang, Psycho-Oncology	2016	41
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040. Aiwu Ruth He, Thomas Yau, Chiun Hsu, Journal of Clinical Oncology PathologyPharmacotherapyNivo MonotherapyImmunotherapyUnited States	2020	37
Longitudinal Changes in and Modifiable Predictors of the Prevalence of Severe Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients over the First Two Years of Bereavement Su‐Ching Kuo, Wen‐Chi Chou, Jen‐Shi Chen, Journal of Palliative Medicine	2016	28

Page 1